The Desirable Life of Clay Siegall

Clay siegall is a co-founder of Seattle Genetics in 1998 and is currently the CEO and chairman of the board. He created Seattle Genetics on a base of scientific innovation, extensive research,self-experience and also driven by the passion for aiding patients. Clay Siegall can well be noticed and credited for developing and introducing antibody-drug conjugates (ADCs) for cancer treatment.
Siegall also serves as on the board of directors of Alder Biopharmaceutical and Mirna Therapeutics of which both are private biotechnology company. He is an author of more than 70 publications and holds 15 patents. He received a Ph.D. in Genetics from George Washington University and a B.S. in zoology from the University of Maryland.

Under Dr. Siegall’s tenure, Seattle Genetics has entered into multiple strategic licenses for its ADC technology, including with Genentech (Roche), Abbvie, GlaxoSmithKline, that have generated more than three hundred million dollars. Across internal and collaborator programs, more than ten ADCs in clinical development use Seattle Genetics’ technology. He has also seen its capital rising to six hundred and seventy-five million dollars through both public and private funding, including the company’s initial public offering in two thousand and one.
Clay Siegall has had several honors and awards in which he has been recognized. In two thousand and twelve, he was honored for being the entrepreneur of the year at Pacific Northwest Ernst and Young. In two thousand and thirteen, he was awarded as an alumnus of the year for computer, math, and natural sciences.
Before co-founding Seattle Genetics, Dr. Siegall was with the National Cancer Institute, the Bristol-Myers Squibb Pharmaceutical Research Institute from the year 1991 to 1997, and National Institutes of health for five years.Clay Siegall is currently the director of Ultragenyx Pharmaceutical.


The Rise of Seattle Genetics under Dr. Siegall

Clay Siegall is one of the co-founders of Seattle Genetics which came up 1998. Currently, he is the company’s Chief Executive Officer, a member of the Board of Directors, and President of Seattle Genetics. The company is coming up with a diverse portfolio of preclinical and clinic product candidates targeting a variety of autoimmune and cancer indications. The firm is also a leader in (ADC) antibody drug conjugate and antibody technologies platforms. Dr. Siegall has spearheaded Seattle Genetics into securing more than $320 million via private and public financings, including the firm’s initial public offering in the year 2001. Also, the company has entered into lots of strategic contracts with companies like Genentech for SGN-40 which is worth more than $870 million, and several other contracts like CuraGen, MedImmune, Progenics, and Bayer which have generated more than $65 million since 2001.

Before the discovery of Seattle Genetics, Dr. Siegall was working with the National Cancer Institute, National Institutes of Health and Bristol-Myers Squibb Pharmaceutical Research Institute. He is a serving member of the Board of Directors of the Washington Biotechnology, Biomedical Association, Fred Hutchinson Cancer Research Business Alliance, and Alder Biopharmaceuticals.

While under Dr. Siegall’s leadership, Seattle Genetics has qualified for lots of contracts for its ADC technology, like the AbbVie, Genentech (Roche), Pfizer and, GlaxoSmithKline which have raked in more than $310 million. Across collaborator and internal programs, they’re more than twenty ADCs in clinical development using Seattle’s technology.

Chief Executive Officer and Chairman of Seattle Genetics, Inc. Dr. Siegall
In January 2014, Dr. Siegall joined Ultragenyx as a member of the board of directors. Currently, he serves as Chief Executive Officer, Chairman of the Board and President of Seattle Genetics. In 1998, Dr. Siegall discovered Seattle Genetics. Dr. Siegall also concurrently serves on the Boards of Directors of Mirna Therapeutics and Alder Bio-Pharmaceuticals which are two privately owned biotechnology firms. Dr. Siegall earned his Ph.D. in Genetics from the University of George Washington and his Bachelor of Science in Zoology from Maryland University.


Seattle Genetics to Increase its Therapies

Clay Siegall is currently the Chief Executive Officer and President of Seattle Genetics. Clay Siegall co-founded Seattle Genetics in the year 1998, and since then, he has also served as the Chairman of the board of directors. The company has worked under the leadership of Dr. Clay to develop a diverse portfolio of preclinical and clinical products that target several cancers and other autoimmune indications.
Seattle Genetics is now leading in the antibody technologies. The first drug from the firm is known as Adcetris. The antibody conjugate from the institution is doing quite well in the market, and it is also helping many people in more than sixty countries in dealing with cancer.

Clay Siegall is also responsible for raising capital for Seattle Genetics. He has led several capital raising operations for the institutions, managing to secure over three hundred and thirty million dollars in both private and public financings.

Apart from raising capital for the company, Clay Siegall has led the company to enter into several strategic collaborations such as the exclusive international partnerships agreement with the Genentech got SGN-40 that was valued at over eight hundred and sixty million dollars and the progenies that have brought over sixty million dollars.

Joe Biden, the Vice President of the United States visited the Seattle Genetics region to recognize the efforts of the company. The CEO of the biotechnology company announced that Seattle Genetics was going to develop twelve therapies that would be used to treat different types of cancers affecting consumers in the modern times. Clay Siegall revealed that his company was testing its first drug first, and it the tests is positive, and the rest will be introduced soon.

Seattle Genetics will also be increasing its employees in the recent future to ensure that the production of the new drugs is successful. The institution is planning to hire the professionals in less than five years so that all the demand from the organization are met.